Table 4 Average DMR methylation change post-treatment (n = 146) by cancer type in childhood cancer patients.

From: Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors

Cancer type

n

Mean change Beta valuea

SD

Min

Median

Max

All samples

32

0.047

0.029

−0.011

0.043

0.104

Haematologicalb

25

0.042

0.027

−0.011

0.039

0.101

Solidb

7

0.062

0.032

0.016

0.055

0.104

  1. SD standard deviation, min minimum, max maximum.
  2. aChange in beta value (post-treatment vs. pre-treatment sample), averaged across the 146 DMRs.
  3. bHaematological cancers include ALL (n = 22), AML (n = 2) and lymphoma (n = 1), while solid tumours include neuroblastoma (n = 5), osteosarcoma (n = 1) and Wilms’ tumour (n = 1), derived from male (n = 20) and female (n = 12) patients. Differences between solid and haematological cancers were not statistically significant (ANOVA p = 0.11).
Back to article page